---
title: "HUIYU PHARMACEUTICAL: Injectable Parecoxib Sodium and Injectable Pemetrexed Disodium have obtained overseas listing approval"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/252806530.md"
description: "HUIYU PHARMACEUTICAL announced that its subsidiaries Seacross Pharma (Europe) Ltd. and Seacross Pharmaceuticals Ltd. have obtained marketing authorizations in the Netherlands and Saudi Arabia, respectively, for injectable Parecoxib Sodium and injectable Pemetrexed Disodium. This authorization will enrich the company's international product pipeline, enhance brand image, and promote the expansion of international business, laying the foundation for sustainable development"
datetime: "2025-08-13T07:56:03.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/252806530.md)
  - [en](https://longbridge.com/en/news/252806530.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/252806530.md)
generator: "portal-rs"
---

# HUIYU PHARMACEUTICAL: Injectable Parecoxib Sodium and Injectable Pemetrexed Disodium have obtained overseas listing approval

According to the Zhitong Finance APP, HUIYU PHARMACEUTICAL (688553.SH) announced that its subsidiaries Seacross Pharma (Europe) Ltd. and Seacross Pharmaceuticals Ltd. have recently received marketing approvals for their products, injectable Parecoxib Sodium and injectable Pemetrexed Disodium, from the Dutch National Institute for Public Health and the Environment and the Saudi Arabian Health Products Regulatory Authority, respectively.

The marketing approvals for injectable Parecoxib Sodium and injectable Pemetrexed Disodium obtained in the Netherlands and Saudi Arabia are beneficial for the company to enrich its product pipeline in the international market, enhance its brand image, and continuously expand the breadth and depth of its international business, further solidifying the foundation for sustainable development in the international market

### Related Stocks

- [688553.CN](https://longbridge.com/en/quote/688553.CN.md)

## Related News & Research

- [WUXI APPTEC Reportedly Sells 2.6% Stake in WUXI XDC for Up to HKD2.4B](https://longbridge.com/en/news/297110148.md)
- [China Was the Outlier to Lego's Broad-Based Revenue Growth in First Half, CEO Says](https://longbridge.com/en/news/297007458.md)
- [03:39 ETWalovi Accelerates Global Push with WALOVI Singapore HQ Launch and Trio of Southeast Asia Deals](https://longbridge.com/en/news/297003145.md)
- [BeOne says FDA approves Tevimbra-based first-line regimen for HER2+ gastroesophageal cancer](https://longbridge.com/en/news/296930925.md)
- [A: Q3 results exceeded expectations with strong growth in pharma, CDMO, and China, driving raised FY26 guidance](https://longbridge.com/en/news/297095880.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**